CAR T Global Consultant Inc., a specialized consulting company in the realm of Cell & Gene Therapy, is thrilled to unveil its latest offering—a Contract Cell & Gene Therapy Organization (CGT CCO). This innovative service is crafted to provide Biotech companies with a comprehensive go-to-market commercialization solution while enabling them to retain ownership of their intellectual property.

Guillaume Köszegi, Founder and President of CAR T Global Consultant, underscores the limited commercialization options available to Biotechs, typically confined to either out-licensing/selling their assets to larger firms or establishing an independent commercialization structure. The latter often requires significant resources and expertise that many Biotech companies may lack. CAR T Global Consultant aims to address this gap with a hybrid model, allowing companies to maintain control over their assets while outsourcing commercialization services. This approach permits them to focus on R&D investments, utilizing a flexible arrangement until specific milestones are achieved or as long as necessary.

Mr. Köszegi emphasizes the unique challenges of the Cell & Gene Therapy field, citing specific logistical, technical, scientific, and regulatory requirements. The CGT CCO service will provide specialized teams with expertise in crucial areas such as Medical Affairs, Sales, Site Onboarding, Market Access, and Regulatory Affairs, streamlining the intricate process for Biotech companies.

With 1369 cell and gene therapy developers worldwide conducting over 2000 ongoing clinical trials, most in Phase 2 and Phase 3, the demand for efficient commercialization solutions is critical. CAR T Global Consultant positions itself as a key player in ensuring the timely and effective market entry of novel agents to address various niche disease populations.

The establishment of the Full-Service Cell & Gene Therapy Specific Contract Commercialization Organization (CGT CCO) marks another milestone in CAR T Global Consultant's mission to support cell & gene therapy organizations. Through impeccable execution, the company aims to expedite the delivery of important assets to patients without unnecessary delays.

 

Source: prnewswire.com

Report Abuse